Table 2.
Safety profile of secukinumab during the study
| n (%) (N = 306) | |
|---|---|
| Any AE | 126 (41.2) |
| Any SAE | 22 (7.2) |
| AR | 74 (24.2) |
| AE leading to treatment discontinuation | 20 (6.5) |
| Death | 0 |
| AE | AR | |
|---|---|---|
| Nasopharyngitis | 15 (4.9) | 5 (1.6) |
| Oral candidiasis | 9 (2.9) | 9 (2.9) |
| Psoriasis | 14 (4.6) | 7 (2.3) |
| Generalized pruritus | 7 (2.3) | 4 (1.3) |
| Psoriatic arthropathy | 8 (2.61) | 2 (0.7) |
Incidence of AE of 2% or more is presented. Multiple episodes of an event (preferred term) in the same patient are counted only once. MedDRA version 22.0. AE, adverse event; AR, adverse reaction; N, total number of patients; n, number of patients; SAE, serious AE.